Evidence map›Paper›PMID 31289275›Full record

ArticleNature communications2019

Identification of a pro-angiogenic functional role for FSP1-positive fibroblast subtype in wound healing.

Sarika Saraswati, Stephanie M W Marrow, Lester A Watch, Pampee P Young

Abstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. CD34Theranostics · 2025
    Article
  13. Review
  14. Review
  15. iScience · 2024
    Article
  16. Fibroblasts in Diabetic Foot Ulcers.International journal of molecular sciences · 2024
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sarika SaraswatiDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. sarika.saraswati@vumc.org.ORCID http://orcid.org/0000-0002-5674-8371
Stephanie M W MarrowDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Lester A WatchDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Pampee P YoungDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. pampee.young@redcross.org.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
VANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7M
Vanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3M
Elucidating fibroblast heterogeneity as a pathway to target organ fibrosisR01GM118300 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SARASWATI, SARIKA · 2016 to 2019
$1.2M
Thermosensitive injectable polymer-based stem cell therapy for limb ischemiaR21EB019509 · NIBIB · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SUNG, HAK-JOON, YOUNG, PAMPEE P · 2015 to 2016
$433k
Leica Bond RXS10OD023475 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOYD, KELLI L. · 2018 to 2018
$213k
NCI NIH HHS P30 CA068485NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIBIB NIH HHS R21 EB019509NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIDDK NIH HHS U2C DK059637NIGMS NIH HHS R01 GM118300NIH HHS S10 OD023475U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM118300
6 · The paper itself

Abstract

Fibrosis accompanying wound healing can drive the failure of many different organs. Activated fibroblasts are the principal determinants of post-injury pathological fibrosis along with physiological repair, making them a difficult therapeutic target. Although activated fibroblasts are phenotypically heterogeneous, they are not recognized as distinct functional entities. Using mice that express GFP under the FSP1 or αSMA promoter, we characterized two non-overlapping fibroblast subtypes from mouse hearts after myocardial infarction. Here, we report the identification of FSP1-GFP

Indexed as

ActinsAnimalsBone Marrow TransplantationCalcium-Binding ProteinsCell DifferentiationDisease Models, AnimalFibroblastsFibrosisGreen Fluorescent ProteinsHumansHuman Umbilical Vein Endothelial CellsMiceMice, Inbred C57BLMice, TransgenicMyocardial InfarctionMyocardiumACTA2 protein, humanActa2 protein, mouseActinsCalcium-Binding ProteinsGreen Fluorescent ProteinsS100A4 protein, humanS100a4 protein, mouseS100 Calcium-Binding Protein A4

Identifiers

PMID31289275
PMCPMC6617456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.